Pfizer’s Ibrance successor moves forward with new study data
Source: BioPharma Dive - Latest News
The drug, which one analyst described as a “critical” part of Pfizer’s oncology strategy, represents a possible improvement upon Ibrance and other, similar breast cancer medicines from Eli Lilly and Novartis.